SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) ("Cuprina" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed ...